Skip to main content

#156412

NHE-1 expressing PS120 cell line

Cat. #156412

NHE-1 expressing PS120 cell line

Cat. #: 156412

Unit size: 1x10^6 cells / vial

Availability: 10-12 weeks

Disease: Cardiac ischemia

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Mark Donowitz

Institute: Johns Hopkins University

Tool Details
Target Details
Handling

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: NHE-1 expressing PS120 cell line
  • Research fields: Cell signaling and signal transduction;Drug development
  • Parental cell: CCL39
  • Disease: Cardiac ischemia
  • Description: An isoform of the Na+/H+ exchanger, NHE-1, has been cloned, sequenced and stably expressed in PS120 fibroblast cells. PS120 being a Na+/H+ exchanger deficient derivative of the CCL39 cell line, poses no background in experimental studies. The NHE cDNA was cloned and sequenced from a rabbit ileal villus cell cDNA library. The cells were then stably transfected using double selection with G418 and acid selection. The Na+/H+ exchange activity of these cells were proven using fluorescence measurement using a pH sensitive dye. These cells are ideal for the Na+/H+ exchanger functional studies as well as drug effect studies with null background. Additional advantages include:â?‚€?‹Â˜ NHE-1 aids in the development of treatment for cardiac ischemia

Target Details

  • Target: Na+/H+ exchanger

Handling

  • Format: Frozen
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.